Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
A general strategy for the use of allogeneic lymphocyte infusions in the treatment of disorders characterized by impaired helper or suppressor T cell function: autoimmune diseases and the acquired immunodeficiency syndrome (AIDS).
Abstract:
Allogeneic lymphocytes can exert very potent non-specific immunomodulatory effects both in vitro and in vivo. Repeated infusions of allogeneic suppressor or helper populations may find use in the treatment of diseases characterized by impaired suppressor function (such as many autoimmune diseases) or impaired helper function (such as AIDS), respectively. Nutritional adjuvants for use with allogeneic suppressor therapy may include essential fatty acids, zinc, selenium, and vitamin E; the latter two nutrients as well as vitamin C and beta carotene may have value as adjuvants for allogeneic helper therapy. In a small preliminary trial, long-lasting normalization of rheumatoid factor titers and clinical symptoms has been achieved in 5 of 7 cases of chronic rheumatoid arthritis treated with allogeneic lymphocyte infusions, selenium, and vitamin E. These results indicate that allogeneic lymphocyte infusions accompanied by antioxidant support can promote the induction of new appropriate suppressor activity in the host. This phenomenon of allogeneic suppressor induction may be more clinically important than direct allosuppression of host B cells under the conditions of this study, and may find application in the treatment of a number of autoimmune disorders.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Autoimmune Diseases/IMMUNOLOGY/*THERAPY *Blood Transfusion Human Immune Tolerance Lymphocytes/*TRANSPLANTATION T-Lymphocytes, Helper-Inducer/*IMMUNOLOGY T-Lymphocytes, Suppressor-Effector/*IMMUNOLOGY Transplantation, Homologous JOURNAL ARTICLE REVIEW
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
